Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021

Objetivo: Determinar el valor predictivo de las troponinas cardíacas para mortalidad intrahospitalaria en adultos hospitalizados con COVID-19 durante enero a junio de 2021. Materiales y métodos: Estudio de casos y controles anidado en una cohorte retrospectiva, que incluyó sujetos de 18 años en adel...

Full description

Autores:: Murgas Cañas, Carlos Hernando
Ospino Guerra, María Clara

Tipo de recurso:

Fecha de publicación:: 2023

Institución:: Universidad Libre

Repositorio:: RIU - Repositorio Institucional UniLibre

Idioma:

id	RULIBRE2_1ebc12d396f0f883a3e8577d8b67f478
oai_identifier_str	oai:repository.unilibre.edu.co:10901/28377
network_acronym_str	RULIBRE2
network_name_str	RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
title	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
spellingShingle	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021 COVID-19 Mortalidad Troponinas Valor predictivo Injuria miocárdica COVID-19 Mortality Troponins Predictive value Myocardial injury Troponina Infecciones por coronavirus - mortalidad Infarto del miocardio
title_short	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
title_full	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
title_fullStr	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
title_full_unstemmed	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
title_sort	Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021
dc.creator.fl_str_mv	Murgas Cañas, Carlos Hernando Ospino Guerra, María Clara
dc.contributor.advisor.none.fl_str_mv	Cano Rivera, Rodolfo Varela Prieto, Lourdes
dc.contributor.author.none.fl_str_mv	Murgas Cañas, Carlos Hernando Ospino Guerra, María Clara
dc.subject.spa.fl_str_mv	COVID-19 Mortalidad Troponinas Valor predictivo Injuria miocárdica
topic	COVID-19 Mortalidad Troponinas Valor predictivo Injuria miocárdica COVID-19 Mortality Troponins Predictive value Myocardial injury Troponina Infecciones por coronavirus - mortalidad Infarto del miocardio
dc.subject.subjectenglish.spa.fl_str_mv	COVID-19 Mortality Troponins Predictive value Myocardial injury
dc.subject.lemb.spa.fl_str_mv	Troponina Infecciones por coronavirus - mortalidad Infarto del miocardio
description	Objetivo: Determinar el valor predictivo de las troponinas cardíacas para mortalidad intrahospitalaria en adultos hospitalizados con COVID-19 durante enero a junio de 2021. Materiales y métodos: Estudio de casos y controles anidado en una cohorte retrospectiva, que incluyó sujetos de 18 años en adelante con diagnóstico confirmado de COVID-19 hospitalizados entre enero y junio de 2021; se describieron las variables demográficas y paraclínicas de los pacientes y su relación con la condición al egreso; se estimaron las características operativas (sensibilidad, especificidad y valores predictivos) de las troponinas elevadas frente a la mortalidad. Resultados: Se incluyeron 358 participantes, de los cuales 47,8% eran mujeres, la edad promedio fue de 65,1+/-14,9 años. Las comorbilidades más frecuentes fueron hipertensión arterial (53,1%), obesidad (31,6%) y diabetes mellitus (21,5%). Todas las variables estudiadas (excepto el sexo) presentaron diferencias estadísticamente significativas (p<0,05) respecto a mortalidad, siendo la elevación de troponinas el principal factor, con un OR de 9,4 (IC95%: 5,5-16,0). Los pacientes con elevación de troponinas presentaron una mortalidad intrahospitalaria mayor (55,6%) frente al grupo sin elevación (11,7%). La sensibilidad y especificidad de este biomarcador fue de 77,9% y 72,7% respectivamente. El valor predictivo positivo de la elevación de troponinas fue de 55,6% y su valor predictivo negativo fue de 88,3% para mortalidad intrahospitalaria. Conclusión: La elevación de troponinas en los sujetos con COVID-19 tiene una correlación positiva con la mortalidad intrahospitalaria de forma independiente a otras condiciones como grupo etario, comorbilidades o requerimiento de oxigenoterapia. Por otro lado, las troponinas normales tienen un buen valor predictivo negativo que permite predecir mayor probabilidad de supervivencia al egreso.
publishDate	2023
dc.date.created.none.fl_str_mv	2023
dc.date.accessioned.none.fl_str_mv	2024-02-07T19:42:41Z
dc.date.available.none.fl_str_mv	2024-02-07T19:42:41Z
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.spa.fl_str_mv	Tesis de Especialización
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/10901/28377
url	https://hdl.handle.net/10901/28377
dc.relation.references.spa.fl_str_mv	Woodall MNJ, Masonou T, Case KM, Smith CM. Human models for COVID- 19 research. J Physiol. 2021;599(18):4255–67 Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020;16(12):1159–84 Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25 Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta- analysis. J Med Virol. 2020;92(10):1875–83 Zinellu A, Sotgia S, Fois AG, Mangoni AA. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta- regression. Adv Med Sci. 2020;66(2):304–14 Beltrán FM. La Sociedad Colombiana de Cardiología y Cirugía Cardiovascular y la pandemia COVID-19. Rev Colomb Cardiol. 2020;27(2):69–72 Saavedra CA. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio. 2020;24(3):1–2 Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):1–7 McKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol. 2021;37(8):1165–74 Cañón-Montañez W, Santos ÁBS, Foppa M. Strain longitudinal global: un parámetro útil para evaluar disfunción ventricular izquierda subclínica en el síndrome metabólico. Rev Colomb Cardiol. 2016;23(2):112–9 Sun W, Zhang Y, Wu C, Xie Y, Peng L, Nie X, et al. Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients. Echocardiography. 2021;38(8):1272–81 Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, et al. 60 Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study. Europace. 2021;23(10):1603–11 Hendren NS, Drazner MH, Bozkurt B. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome Middle Eastern respiratory syndrome. Circulation. 2020;9(141):1903–1914 Sattar Y, Ullah W, Rauf H, Virk H ul H, Yadav S, Chowdhury M, et al. COVID- 19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Hear Vasc [Internet]. 2020;29(2020):100589. Available from: https://doi.org/10.1016/j.ijcha.2020.100589 Cannata F, Bombace S, Stefanini GG. Marcadores cardiacos en pacientes con COVID-19: un instrumento práctico en tiempos difíciles. Rev Española Cardiol. 2021;10–2 Stefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8 Qin JJ, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension. 2020;1104–12 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62 Deng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. Clin Chim Acta [Internet]. 2020; 510:186–90. Available from: https://doi.org/10.1016/j.cca.2020.07.018 Junior GLG de A, Braga F, Jorge JK, Nobre GF, Kalichsztein M, de Faria P de MP, et al. Prognostic value of troponin-t and b-type natriuretic peptide in patients hospitalized for covid-19. Arq Bras Cardiol. 2020;115(4):660–6 Omland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(19):1878–80 Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute 61 Respiratory Distress Syndrome. Circulation. 2021;553–65 Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8 Yu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4 Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831–40 Clerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A, et al. COVID- 19 and cardiovascular disease. Circulation. 2020;141(20):1648–55 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506 Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol. 2020;30(5):2616–26 Vélez M, Velásquez P, Acosta J, Vera C, Santiago J, Jimenez C, et al. Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NS Manocha KK, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the Ha2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021;10(6 Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10 Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun;42(23):2270–9 Yitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 62 disease: A systematic review. SAGE open Med. 2021; 9:20503121211050756 Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245–9 Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020; 8:49 Bartziokas K, Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Vol. 156, Medicina clinica. Spain; 2021. p. 37 Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021 Apr;156(7):324–31 Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11 November):1–23 Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One [Internet]. 2020;15(10 October):1–25. Available from: http://dx.doi.org/10.1371/journal.pone.0239802 Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res [Internet]. 2020;25(1):1–10. Available from: https://doi.org/10.1186/s40001-020-00432-3 Ali AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, Inflamm Dis. 2022;10(3):1–10 Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95(January):304–7 McKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol [Internet]. 2020; Available from: https://doi.org/10.1016/j.cjca.2020.11.007 Papageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol [Internet]. 2022;77(1):81–8. Available from: https://doi.org/10.1080/00015385.2021.1887586 Zhu F, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(January):164–71 Al B, Torres P, Ramos-tuarez F, Dewaswala N, Abdallah A. Cardiac Troponin- I and COVID-19: A Prognostic Tool for In-Hospital Mortality. 2020;11(6):398– 404 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9 Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from: https://doi.org/10.1080/10408363.2020.1770685 Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020 Aug;106(15):1127–31
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	http://purl.org/coar/access_right/c_abf2
dc.format.spa.fl_str_mv	PDF
dc.coverage.spatial.spa.fl_str_mv	Barranquilla
institution	Universidad Libre
bitstream.url.fl_str_mv	http://repository.unilibre.edu.co/bitstream/10901/28377/8/MURGAS.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/28377/9/FORMULARIO%20AUTORIZACION.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/28377/3/license.txt http://repository.unilibre.edu.co/bitstream/10901/28377/1/MURGAS.pdf http://repository.unilibre.edu.co/bitstream/10901/28377/2/FORMULARIO%20AUTORIZACION.pdf
bitstream.checksum.fl_str_mv	58c92cdbcff86d719a333c29a061920d ec164fe5ea3a606e57efc3a7014f48c4 8a4605be74aa9ea9d79846c1fba20a33 cf292fccd1850b1543b9c6dbb614a9e2 ea917fd188c64a3aadd00ea15466cb3e
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Unilibre
repository.mail.fl_str_mv	repositorio@unilibrebog.edu.co
_version_	1814090574254309376
spelling	Cano Rivera, RodolfoVarela Prieto, LourdesMurgas Cañas, Carlos HernandoOspino Guerra, María ClaraBarranquilla2024-02-07T19:42:41Z2024-02-07T19:42:41Z2023https://hdl.handle.net/10901/28377Objetivo: Determinar el valor predictivo de las troponinas cardíacas para mortalidad intrahospitalaria en adultos hospitalizados con COVID-19 durante enero a junio de 2021. Materiales y métodos: Estudio de casos y controles anidado en una cohorte retrospectiva, que incluyó sujetos de 18 años en adelante con diagnóstico confirmado de COVID-19 hospitalizados entre enero y junio de 2021; se describieron las variables demográficas y paraclínicas de los pacientes y su relación con la condición al egreso; se estimaron las características operativas (sensibilidad, especificidad y valores predictivos) de las troponinas elevadas frente a la mortalidad. Resultados: Se incluyeron 358 participantes, de los cuales 47,8% eran mujeres, la edad promedio fue de 65,1+/-14,9 años. Las comorbilidades más frecuentes fueron hipertensión arterial (53,1%), obesidad (31,6%) y diabetes mellitus (21,5%). Todas las variables estudiadas (excepto el sexo) presentaron diferencias estadísticamente significativas (p<0,05) respecto a mortalidad, siendo la elevación de troponinas el principal factor, con un OR de 9,4 (IC95%: 5,5-16,0). Los pacientes con elevación de troponinas presentaron una mortalidad intrahospitalaria mayor (55,6%) frente al grupo sin elevación (11,7%). La sensibilidad y especificidad de este biomarcador fue de 77,9% y 72,7% respectivamente. El valor predictivo positivo de la elevación de troponinas fue de 55,6% y su valor predictivo negativo fue de 88,3% para mortalidad intrahospitalaria. Conclusión: La elevación de troponinas en los sujetos con COVID-19 tiene una correlación positiva con la mortalidad intrahospitalaria de forma independiente a otras condiciones como grupo etario, comorbilidades o requerimiento de oxigenoterapia. Por otro lado, las troponinas normales tienen un buen valor predictivo negativo que permite predecir mayor probabilidad de supervivencia al egreso.Universidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina InternaGhio S, Montalto C, Pagnesi M, Lupi L, Cappelletti A, Baldetti L, et al. High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? J Cardiovasc Med (Hagerstown). 2021;22(11):828– 31Objective: To determine the predictive value of cardiac troponins for in-hospital mortality in hospitalized adults with COVID-19 from January to June 2021. Methods and materials: Cases and controls nested in a retrospective cohort study. It included people with 18 years old and older with a confirmed diagnosis of COVID-19 hospitalized between January and June 2021, the demographic and paraclinical variables of them and their relationship with the final condition of the patient were described. There were estimated sensibility, specificity, and predictive values of high troponins with respect of mortality. Results: There were included 358 patients, of whom 47.8% were women, and the average age was 65.1+/-14.9 years. The most frequent comorbidities were hypertension (53.1%), obesity (31.6%) and diabetes mellitus (21.5%). All the variables studied (except sex) had statistically significant differences (p<0.05) with mortality, with troponin elevation being the main factor, with an OR of 9.4 (95% CI: 5.5-16.0). Patients with troponin elevation had higher in-hospital mortality (55.6%) compared with the non-elevation group (11.7%). The sensitivity and specificity of this biomarker was 77.9% and 72.7% respectively. The positive predictive value of troponin elevation was 55.6% and its negative predictive value was 88.3% for in-hospital mortality. Conclusion: Troponin elevation in patients with COVID-19 has a positive correlation with in-hospital mortality independently of other conditions such as age, comorbidities, or oxygen therapy requirement. On the other hand, normal troponins have a good negative predictive value that allows predicting a greater probability of survival at discharge.PDFCOVID-19MortalidadTroponinasValor predictivoInjuria miocárdicaCOVID-19MortalityTroponinsPredictive valueMyocardial injuryTroponinaInfecciones por coronavirus - mortalidadInfarto del miocardioValor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021Tesis de Especializacióninfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fWoodall MNJ, Masonou T, Case KM, Smith CM. Human models for COVID- 19 research. J Physiol. 2021;599(18):4255–67Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020;16(12):1159–84Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta- analysis. J Med Virol. 2020;92(10):1875–83Zinellu A, Sotgia S, Fois AG, Mangoni AA. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta- regression. Adv Med Sci. 2020;66(2):304–14Beltrán FM. La Sociedad Colombiana de Cardiología y Cirugía Cardiovascular y la pandemia COVID-19. Rev Colomb Cardiol. 2020;27(2):69–72Saavedra CA. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio. 2020;24(3):1–2Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):1–7McKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol. 2021;37(8):1165–74Cañón-Montañez W, Santos ÁBS, Foppa M. Strain longitudinal global: un parámetro útil para evaluar disfunción ventricular izquierda subclínica en el síndrome metabólico. Rev Colomb Cardiol. 2016;23(2):112–9Sun W, Zhang Y, Wu C, Xie Y, Peng L, Nie X, et al. Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients. Echocardiography. 2021;38(8):1272–81Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, et al. 60 Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study. Europace. 2021;23(10):1603–11Hendren NS, Drazner MH, Bozkurt B. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome Middle Eastern respiratory syndrome. Circulation. 2020;9(141):1903–1914Sattar Y, Ullah W, Rauf H, Virk H ul H, Yadav S, Chowdhury M, et al. COVID- 19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Hear Vasc [Internet]. 2020;29(2020):100589. Available from: https://doi.org/10.1016/j.ijcha.2020.100589Cannata F, Bombace S, Stefanini GG. Marcadores cardiacos en pacientes con COVID-19: un instrumento práctico en tiempos difíciles. Rev Española Cardiol. 2021;10–2Stefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8Qin JJ, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension. 2020;1104–12Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62Deng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. Clin Chim Acta [Internet]. 2020; 510:186–90. Available from: https://doi.org/10.1016/j.cca.2020.07.018Junior GLG de A, Braga F, Jorge JK, Nobre GF, Kalichsztein M, de Faria P de MP, et al. Prognostic value of troponin-t and b-type natriuretic peptide in patients hospitalized for covid-19. Arq Bras Cardiol. 2020;115(4):660–6Omland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(19):1878–80Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute 61 Respiratory Distress Syndrome. Circulation. 2021;553–65Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8Yu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831–40Clerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A, et al. COVID- 19 and cardiovascular disease. Circulation. 2020;141(20):1648–55Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol. 2020;30(5):2616–26Vélez M, Velásquez P, Acosta J, Vera C, Santiago J, Jimenez C, et al. Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NSManocha KK, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the Ha2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021;10(6Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun;42(23):2270–9Yitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 62 disease: A systematic review. SAGE open Med. 2021; 9:20503121211050756Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245–9Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020; 8:49Bartziokas K, Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Vol. 156, Medicina clinica. Spain; 2021. p. 37Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021 Apr;156(7):324–31Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11 November):1–23Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One [Internet]. 2020;15(10 October):1–25. Available from: http://dx.doi.org/10.1371/journal.pone.0239802Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res [Internet]. 2020;25(1):1–10. Available from: https://doi.org/10.1186/s40001-020-00432-3Ali AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, Inflamm Dis. 2022;10(3):1–10Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95(January):304–7McKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol [Internet]. 2020; Available from: https://doi.org/10.1016/j.cjca.2020.11.007Papageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol [Internet]. 2022;77(1):81–8. Available from: https://doi.org/10.1080/00015385.2021.1887586Zhu F, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(January):164–71Al B, Torres P, Ramos-tuarez F, Dewaswala N, Abdallah A. Cardiac Troponin- I and COVID-19: A Prognostic Tool for In-Hospital Mortality. 2020;11(6):398– 404Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from: https://doi.org/10.1080/10408363.2020.1770685Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020 Aug;106(15):1127–31http://purl.org/coar/access_right/c_abf2THUMBNAILMURGAS.pdf.jpgMURGAS.pdf.jpgPortadaimage/jpeg86736http://repository.unilibre.edu.co/bitstream/10901/28377/8/MURGAS.pdf.jpg58c92cdbcff86d719a333c29a061920dMD58FORMULARIO AUTORIZACION.pdf.jpgFORMULARIO AUTORIZACION.pdf.jpgIM Thumbnailimage/jpeg28797http://repository.unilibre.edu.co/bitstream/10901/28377/9/FORMULARIO%20AUTORIZACION.pdf.jpgec164fe5ea3a606e57efc3a7014f48c4MD59LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/28377/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALMURGAS.pdfMURGAS.pdfapplication/pdf1232832http://repository.unilibre.edu.co/bitstream/10901/28377/1/MURGAS.pdfcf292fccd1850b1543b9c6dbb614a9e2MD51FORMULARIO AUTORIZACION.pdfFORMULARIO AUTORIZACION.pdfapplication/pdf637216http://repository.unilibre.edu.co/bitstream/10901/28377/2/FORMULARIO%20AUTORIZACION.pdfea917fd188c64a3aadd00ea15466cb3eMD5210901/28377oai:repository.unilibre.edu.co:10901/283772024-08-28 06:01:17.394Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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

Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021

Publicaciones similares